Novo Nordisk ~40% market share (current leader) Wegovy delivers ~15% weight loss Strong GLP-1 dominance & oral semaglutide push Facing supply constraints Eli Lilly ~35% and rapidly growing Zepbound delivers ~2022% weight loss (best-in-class) Aggressive innovation with dual & triple agonists Massive global expansion & investments Pipeline Battle CagriSema (Novo): ~2025% expected weight loss Retatrutide (Lilly): ~24%+ (next-gen triple agonist) Whats really happening
doi: 10.1016/j.semcdb.2018.03.004 134 WeiJ.AlfajaroM
Before your cellulite injection, you may want to consider asking the following questions: whether these injections can be combined with other treatments, where else cellulite injections can be used, and other benefits these injections offer beyond cellulite reduction
Cons: Vary in absorption and efficiency, potentially longer periods to observe health benefits, no skin-lightening effect, and requires consistent long-term use to maintain levels
A growing, though still nascent, body of evidence provides compelling cases for OoC predictivity
Pensacola Physical Medicine offers our patient form(s) online so they can be completed in the convenience of your own home or office
